CF PHARMTECH2652.HKValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Deeply Undervalued” zone.
As of Oct 16, 2026, CF PHARMTECH (2652.HK) trades at a negative P/E (-323.04x, due to a recent net loss), P/B of 1.68x, P/S of 5.20x, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E historical percentile is still accumulating data over the trailing long-term window (vs. the short-term percentile still accumulating data); P/B sits at the 2nd percentile over the trailing 10Y window (vs. 2nd percentile over 3Y); P/S sits at the 2nd percentile over the trailing 10Y window (vs. 2nd percentile over 3Y).
Cross-sectional valuation: its P/B ranks at the 64th percentile within its industry and the 69th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 1.58%, ranking at the 100th percentile over the trailing 20Y window.
Its P/B percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here lean heavily on buybacks rather than cash dividends. CF PHARMTECH operates in the Pharmaceutical Chemistry sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: HKG: 2652 · SEHK: 2652 · 2652
Want the full picture on whether CF PHARMTECH (2652.HK) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | -323.04 | Negative | Negative | Negative | Negative | Negative | Negative |
| P/B (MRQ) | 1.68 | ||||||
| P/S (TTM) | 5.20 | ||||||
| Dividend Yield | 0.00% | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback + Div Yield | 1.58% |